The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for PMV Pharmaceuticals Inc. (PMVP) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.005, or -0.08%, to $5.90. The PMV Pharmaceuticals Inc. has recorded 3,473 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
PMV Pharmaceuticals Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $5.91 and fluctuated between $6.19 as its day high and $5.78 as its day low. The current market capitalization of PMV Pharmaceuticals Inc. is $274.52M. A total of 0.8 million shares were traded on the day, compared to an average of 522.06K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, PMVP has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 5 BUYs and 5 SELLs from insiders. Insiders purchased 143,250 shares during that period but sold 503,313.
In the most recent transaction, ORBIMED ADVISORS LLC sold 26,253 shares of PMVP for 15.93 per share on May 26. After the transaction, the 10% Owner now owns 87,786 company shares. In a previous transaction on Mar 31, ORBIMED ADVISORS LLC sold 34,500 shares at 21.17 per share. PMVP shares that 10% Owner owns now total 0.
Among the insiders who sold shares, ORBIMED ADVISORS LLC disposed of 75,000 shares on Mar 30 at a per-share price of $22.39. This resulted in the 10% Owner holding 34,500 shares of PMVP after the transaction. In another insider transaction, ORBIMED ADVISORS LLC sold 365,000 shares at $21.52 per share on Mar 29. Company shares held by the 10% Owner now total 109,500.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for PMVP in the last 3 months, the mean price target is $17.75 with high estimates of $20.00 and low estimates of $15.00. In terms of 52-week highs and lows, PMVP has a high of $24.26 and a low of $6.09.
As of this writing, PMVP has an earnings estimate of -$0.44 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.41 per share and a lower estimate of -$0.45. The company reported an EPS of -$0.38 in the last quarter, which was 7.30% higher than expectations of -$0.41.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PMVP is Overweight with a score of 5.00. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.